[1] LIU S, YANG L, YUAN Y, et al.Cancer incidence in Beijing, 2014[J].Chin J Cancer Res, 2018, 30(1):13. doi: 10.21147/j.issn.1000-9604.2018.01.02
[2] YUAN J, LI J, CHEN X, et al.Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma[J].Bull Cancer, 2017, 104(6):516. doi: 10.1016/j.bulcan.2017.03.005
[3] LIANG K, HE L, DONG W, et al.Risk factors of central lymph node metastasis in cN0 papillary thyroid carcinoma:a study of 529 patients[J].Med Sci Monit, 2014, 20:807. doi: 10.12659/MSM.890182
[4] HU DX, ZHOU J, HE W, et al.Risk factors of lateral lymph node metastasis in cN0 papillary thyroid carcinoma[J].World J Surg Oncol, 2018, 16:30 doi: 10.1186/s12957-018-1336-3
[5] LIU C, CHEN T, LIU Z, et al.Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma:a meta-analysis[J].World J Surg Oncol, 2016, 14:241. doi: 10.1186/s12957-016-0979-1
[6] SONG JY, SUN SR, DONG F, et al.Predictive value ofBRAFV600E mutation for lymph node metastasis in papillary thyroid cancer:a meta-analysis[J].Curr Med Sci, 2018, 38(5):785. doi: 10.1007/s11596-018-1945-7
[7] BANDOH N, AKAHANE T, GOTO T, et al.Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma:a single institution's experience[J].Oncol Lett, 2018, 16:7278.
[8] PARK JY, YI JW, PARK CH, et al.Role of BRAF and RAS mutations in extrathyroidal extension in papillary thyroid cancer[J].Cancer Genomics Proteomics, 2016, 13(2):171.
[9] ZHANG H, CHEN D.Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells[J].Thyroid Res, 2018, 11:13. doi: 10.1186/s13044-018-0057-6
[10] CHERNAYA G, MIKHNO N, KHABALOVA T, et al.The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence ofBRAFV600E mutation[J].Surg Oncol, 2018, 27:702. doi: 10.1016/j.suronc.2018.09.007
[11] CHEN J, LI XL, ZHAO CK, et al.Conventional ultrasound, immunohistochemical factors and BRAFV600E mutation in predicting central cervical lymph node metastasis of papillary thyroid carcinoma[J].Ultrasound Med Biol, 2018, 44:2296. doi: 10.1016/j.ultrasmedbio.2018.06.020
[12] American Thyroid Association(ATA)Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, COOPER DS, DOHERTY GM, et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid, 2009, 19(11):1167. doi: 10.1089/thy.2009.0110
[13] YOO BJ, SONG CM, JI YB, et al.Efficacy of central neck dissection for clinically node-negative papillary thyroid carcinoma:propensity scoring matching[J].Front Endocrinol (Lausanne), 2019, 10:172.. doi: 10.3389/fendo.2019.00172
[14] AGCAOGLU O, SENGUN B, OZORAN E, et al.Should we perform routine prophylactic central neck dissection in patients with thyroid papillarymicrocarcinoma?[J].Ann Ital Chir, 2018, 89:485.
[15] ZHOU C, LI J, WANG Y, et al.Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma[J].Oncol Lett, 2019, 17(1):183.